Sep 9, 2024 | Press Releases
– Statistically significant vocal biomarker speech latency data reinforce the strong efficacy of brilaroxazine for negative symptoms and other key symptom domains of schizophrenia – – Additional vocal biomarker data from ongoing open label extension...
Sep 4, 2024 | Press Releases
CUPERTINO, Calif., Sept. 04, 2024 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...
Aug 27, 2024 | Press Releases
CUPERTINO, Calif., Aug. 27, 2024 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central...
Aug 21, 2024 | Press Releases
CUPERTINO, Calif., Aug. 21, 2024 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central...
Aug 14, 2024 | Press Releases
– Topline data from 1-year open-label extension (OLE) trial expected Q4 2024 – – Registrational RECOVER-2 trial in schizophrenia expected to initiate Q3 2024; topline data expected Q4 2025 – – European patent granted covering...
Aug 6, 2024 | Press Releases
CUPERTINO, Calif., Aug. 06, 2024 — -Similar patent has also been granted in Japan -Brilaroxazine has received Orphan Drug Designation for the treatment of idiopathic pulmonary fibrosis (IPF) Cupertino, Calif., August 6, 2024 – Reviva Pharmaceuticals...
